LETERMOVIR (Prevymis®)

Clinical Indication

Prevention of cytomegalovirus disease after a stem cell transplant


In line with NICE TA591


Date of classification

October 2019


Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.